Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2

Journal of Medicinal Chemistry

Volumn 57, Issue 22, 2014, Pages 9512-9521

  Kong, Xiangqian ^a   Chen, Limin ^a   Jiao, Lianying ^b   Jiang, Xiangrui ^a   Lian, Fulin ^a   Lu, Junyan ^a   Zhu, Kongkai ^a   Du, Daohai ^a   Liu, Jingqiu ^a   Ding, Hong ^a   Zhang, Naixia ^a   Shen, Jingshan ^a   Zheng, Mingyue ^a   Chen, Kaixian ^a   Liu, Xin ^b   Jiang, Hualiang ^a   Luo, Cheng ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; HISTONE H3; METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; EED PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; HISTONE;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFICACY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; LARGE CELL LYMPHOMA; MOLECULAR DOCKING; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; TRANSCRIPTION REGULATION; BINDING COMPETITION; CATALYSIS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE COURSE; GENETICS; LYMPHOMA; METABOLISM; METHYLATION; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN ANALYSIS; PROTEIN PROCESSING; TUMOR CELL LINE;

ASTEMIZOLE; BINDING, COMPETITIVE; CATALYSIS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; HISTONES; HUMANS; LYMPHOMA; MAGNETIC RESONANCE SPECTROSCOPY; METHYLATION; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84913580995     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501230c     Document Type: Article

References (75)

1. Berger, S. L. The complex language of chromatin regulation during transcription Nature 2007, 447, 407-412
2. Kouzarides, T. Chromatin modifications and their function Cell 2007, 128, 693-705
3. Rice, J. C.; Briggs, S. D.; Ueberheide, B.; Barber, C. M.; Shabanowitz, J.; Hunt, D. F.; Shinkai, Y.; Allis, C. D. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains Mol. Cell 2003, 12, 1591-1598
4. Zhang, Y.; Reinberg, D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails Genes Dev. 2001, 15, 2343-2360
5. Izzo, A.; Schneider, R. Chatting histone modifications in mammals Briefings in Functional Genomics 2010, 9, 429-443
6. Greer, E. L.; Shi, Y. Histone methylation: a dynamic mark in health, disease and inheritance Nat. Rev. Genet. 2012, 13, 343-357
7. Wagner, T.; Jung, M. New lysine methyltransferase drug targets in cancer Nat. Biotechnol. 2012, 30, 622-623
8. Copeland, R. A.; Solomon, M. E.; Richon, V. M. Protein methyltransferases as a target class for drug discovery Nat. Rev. Drug Discovery 2009, 8, 724-732
9. Lewis, E. B. A gene complex controlling segmentation in Drosophila Nature 1978, 276, 565-570
10. Margueron, R.; Reinberg, D. The Polycomb complex PRC2 and its mark in life Nature 2011, 469, 343-349
11. Schuettengruber, B.; Cavalli, G. Recruitment of Polycomb group complexes and their role in the dynamic regulation of cell fate choice Development 2009, 136, 3531-3542
12. Zhou, W.; Zhu, P.; Wang, J.; Pascual, G.; Ohgi, K. A.; Lozach, J.; Glass, C. K.; Rosenfeld, M. G. Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation Mol. Cell 2008, 29, 69-80
13. Stock, J. K.; Giadrossi, S.; Casanova, M.; Brookes, E.; Vidal, M.; Koseki, H.; Brockdorff, N.; Fisher, A. G.; Pombo, A. Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells Nat. Cell Biol. 2007, 9, 1428-1435
14. Sparmann, A.; van Lohuizen, M. Polycomb silencers control cell fate, development and cancer Nat. Rev. Cancer 2006, 6, 846-856
15. Whitcomb, S. J.; Basu, A.; Allis, C. D.; Bernstein, E. Polycomb Group proteins: an evolutionary perspective Trends Genet. 2007, 23, 494-502
16. Simon, J. A.; Kingston, R. E. Mechanisms of polycomb gene silencing: knowns and unknowns Nat. Rev. Mol. Cell Biol. 2009, 10, 697-708
17. Czermin, B.; Melfi, R.; McCabe, D.; Seitz, V.; Imhof, A.; Pirrotta, V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites Cell 2002, 111, 185-196
18. Cao, R.; Zhang, Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex Mol. Cell 2004, 15, 57-67
19. Chang, C. J.; Hung, M. C. The role of EZH2 in tumour progression Br. J. Cancer 2012, 106, 243-247
20. Chase, A.; Cross, N. C. Aberrations of EZH2 in cancer Clin. Cancer Res. 2011, 17, 2613-2618
21. Morin, R. D.; Johnson, N. A.; Severson, T. M.; Mungall, A. J.; An, J.; Goya, R.; Paul, J. E.; Boyle, M.; Woolcock, B. W.; Kuchenbauer, F.; Yap, D.; Humphries, R. K.; Griffith, O. L.; Shah, S.; Zhu, H.; Kimbara, M.; Shashkin, P.; Charlot, J. F.; Tcherpakov, M.; Corbett, R.; Tam, A.; Varhol, R.; Smailus, D.; Moksa, M.; Zhao, Y.; Delaney, A.; Qian, H.; Birol, I.; Schein, J.; Moore, R.; Holt, R.; Horsman, D. E.; Connors, J. M.; Jones, S.; Aparicio, S.; Hirst, M.; Gascoyne, R. D.; Marra, M. A. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat. Genet. 2010, 42, 181-185
22. Yap, D. B.; Chu, J.; Berg, T.; Schapira, M.; Cheng, S. W. G.; Moradian, A.; Morin, R. D.; Mungall, A. J.; Meissner, B.; Boyle, M.; Marquez, V. E.; Marra, M. A.; Gascoyne, R. D.; Humphries, R. K.; Arrowsmith, C. H.; Morin, G. B.; Aparicio, S. A. J. R. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation Blood 2011, 117, 2451-2459
23. Sneeringer, C. J.; Scott, M. P.; Kuntz, K. W.; Knutson, S. K.; Pollock, R. M.; Richon, V. M.; Copeland, R. A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20980-20985
24. Beguelin, W.; Popovic, R.; Teater, M.; Jiang, Y. W.; Bunting, K. L.; Rosen, M.; Shen, H.; Yang, S. N.; Wang, L.; Ezponda, T.; Martinez-Garcia, E.; Zhang, H. K.; Zheng, Y. P.; Verma, S. K.; McCabe, M. T.; Ott, H. M.; Van Aller, G. S.; Kruger, R. G.; Liu, Y.; McHugh, C. F.; Scott, D. W.; Chung, Y. R.; Kelleher, N.; Shaknovich, R.; Creasy, C. L.; Gascoyne, R. D.; Wong, K. K.; Cerchietti, L.; Levine, R. L.; Abdel-Wahab, O.; Licht, J. D.; Elemento, O.; Melnick, A. M. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation Cancer Cell 2013, 23, 677-692
25. Knutson, S. K.; Wigle, T. J.; Warholic, N. M.; Sneeringer, C. J.; Allain, C. J.; Klaus, C. R.; Sacks, J. D.; Raimondi, A.; Majer, C. R.; Song, J.; Scott, M. P.; Jin, L.; Smith, J. J.; Olhava, E. J.; Chesworth, R.; Moyer, M. P.; Richon, V. M.; Copeland, R. A.; Keilhack, H.; Pollock, R. M.; Kuntz, K. W. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells Nat. Chem. Biol. 2012, 8, 890-896
26. McCabe, M. T.; Ott, H. M.; Ganji, G.; Korenchuk, S.; Thompson, C.; Van Aller, G. S.; Liu, Y.; Graves, A. P.; Della Pietra, A.; Diaz, E.; LaFrance, L. V.; Mellinger, M.; Duquenne, C.; Tian, X. R.; Kruger, R. G.; McHugh, C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.; Tummino, P. J.; Creasy, C. L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 2012, 492, 108-102
27. Qi, W.; Chan, H. M.; Teng, L.; Li, L.; Chuai, S. N.; Zhang, R. P.; Zeng, J.; Li, M.; Fan, H.; Lin, Y.; Gu, J.; Ardayfio, O.; Zhang, J. H.; Yan, X. X.; Fang, J. L.; Mi, Y.; Zhang, M.; Zhou, T.; Feng, G.; Chen, Z. J.; Li, G. B.; Yang, T.; Zhao, K. H.; Liu, X. H.; Yu, Z. T.; Lu, C. X.; Atadja, P.; Li, E. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 21360-21365
28. Denisenko, O.; Shnyreva, M.; Suzuki, H.; Bomsztyk, K. Point mutations in the WD40 domain of Eed block its interaction with Ezh2 Mol. Cell. Biol. 1998, 18, 5634-5642
29. Cao, R.; Wang, L.; Wang, H.; Xia, L.; Erdjument-Bromage, H.; Tempst, P.; Jones, R. S.; Zhang, Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing Science 2002, 298, 1039-1043
30. Montgomery, N. D.; Yee, D.; Montgomery, S. A.; Magnuson, T. Molecular and functional mapping of EED motifs required for PRC2-dependent histone methylation J. Mol. Biol. 2007, 374, 1145-1157
31. Montgomery, N. D.; Yee, D.; Chen, A.; Kalantry, S.; Chamberlain, S. J.; Otte, A. P.; Magnuson, T. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation Curr. Biol. 2005, 15, 942-947
32. Kim, W.; Bird, G. H.; Neff, T.; Guo, G.; Kerenyi, M. A.; Walensky, L. D.; Orkin, S. H. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer Nat. Chem. Biol. 2013, 9, 643-650
33. Lee, S. T.; Li, Z.; Wu, Z.; Aau, M.; Guan, P.; Karuturi, R. K.; Liou, Y. C.; Yu, Q. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers Mol. Cell 2011, 43, 798-810
34. Xu, K.; Wu, Z. J.; Groner, A. C.; He, H. H.; Cai, C.; Lis, R. T.; Wu, X.; Stack, E. C.; Loda, M.; Liu, T.; Xu, H.; Cato, L.; Thornton, J. E.; Gregory, R. I.; Morrissey, C.; Vessella, R. L.; Montironi, R.; Magi-Galluzzi, C.; Kantoff, P. W.; Balk, S. P.; Liu, X. S.; Brown, M. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent Science 2012, 338, 1465-1469
35. Wee, Z. N.; Li, Z.; Lee, P. L.; Lee, S. T.; Lim, Y. P.; Yu, Q. EZH2-mediated inactivation of IFN-gamma-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer Cell Rep. 2014, 8, 204-216
36. Zinzalla, G.; Thurston, D. E. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future Future Med. Chem. 2009, 1, 65-93
37. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nat. Rev. Drug Discovery 2004, 3, 301-317
38. Shangary, S.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy Annu. Rev. Pharmacol. Toxicol. 2009, 49, 223-241
39. Zhou, H.; Aguilar, A.; Chen, J.; Bai, L.; Liu, L.; Meagher, J. L.; Yang, C. Y.; McEachern, D.; Cong, X.; Stuckey, J. A.; Wang, S. Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity J. Med. Chem. 2012, 55, 6149-6161
40. Zhao, Y.; Yu, S.; Sun, W.; Liu, L.; Lu, J.; McEachern, D.; Shargary, S.; Bernard, D.; Li, X.; Zhao, T.; Zou, P.; Sun, D.; Wang, S. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice J. Med. Chem. 2013, 56, 5553-5561
41. Sun, H.; Lu, J.; Liu, L.; Yi, H.; Qiu, S.; Yang, C. Y.; Deschamps, J. R.; Wang, S. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins J. Med. Chem. 2010, 53, 6361-6367
42. Mullard, A. Protein-protein interaction inhibitors get into the groove Nat. Rev. Drug Discovery 2012, 11, 172-174
43. Smith, M. C.; Gestwicki, J. E. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity Expert Reviews in Molecular Medicine 2012, 14, e16
44. Lu, Y.; Nikolovska-Coleska, Z.; Fang, X.; Gao, W.; Shangary, S.; Qiu, S.; Qin, D.; Wang, S. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy J. Med. Chem. 2006, 49, 3759-3762
45. Kong, X. Q.; Qin, J.; Li, Z.; Vultur, A.; Tong, L. J.; Feng, E. G.; Rajan, G.; Liu, S. E.; Lu, J. Y.; Liang, Z. J.; Zheng, M. Y.; Zhu, W. L.; Jiang, H. L.; Herlyn, M.; Liu, H.; Marmorstein, R.; Luo, C. Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization Org. Biomol. Chem. 2012, 10, 7402-7417
46. Carlsson, J.; Coleman, R. G.; Setola, V.; Irwin, J. J.; Fan, H.; Schlessinger, A.; Sali, A.; Roth, B. L.; Shoichet, B. K. Ligand discovery from a dopamine D3 receptor homology model and crystal structure Nat. Chem. Biol. 2011, 7, 769-778
47. London, N.; Miller, R. M.; Krishnan, S.; Uchida, K.; Irwin, J. J.; Eidam, O.; Gibold, L.; Cimermancic, P.; Bonnet, R.; Shoichet, B. K.; Taunton, J. Covalent docking of large libraries for the discovery of chemical probes. Nat. Chem. Biol. [Online Early Access] DOI: 10.1038/nchembio.1666; Published Online Oct 26, 2014
48. Janssens, M. M. Astemizole. A nonsedating antihistamine with fast and sustained activity Clin. Rev. Allergy 1993, 11, 35-63
49. Han, Z.; Xing, X.; Hu, M.; Zhang, Y.; Liu, P.; Chai, J. Structural basis of EZH2 recognition by EED Structure 2007, 15, 1306-1315
50. Wendel, H. G.; De Stanchina, E.; Fridman, J. S.; Malina, A.; Ray, S.; Kogan, S.; Cordon-Cardo, C.; Pelletier, J.; Lowe, S. W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 2004, 428, 332-337
51. Garcia-Quiroz, J.; Camacho, J. Astemizole: an old anti-histamine as a new promising anti-cancer drug Anti-Cancer Agents in Medicinal Chemistry 2011, 11, 307-314
52. Garcia-Ferreiro, R. E.; Kerschensteiner, D.; Major, F.; Monje, F.; Stuhmer, W.; Pardo, L. A. Mechanism of block of hEag1 K+ channels by imipramine and astemizole J. Gen. Physiol. 2004, 124, 301-317
53. Diaz, L.; Ceja-Ochoa, I.; Restrepo-Angulo, I.; Larrea, F.; Avila-Chavez, E.; Garcia-Becerra, R.; Borja-Cacho, E.; Barrera, D.; Ahumada, E.; Gariglio, P.; Alvarez-Rios, E.; Ocadiz-Delgado, R.; Garcia-Villa, E.; Hernandez-Gallegos, E.; Camacho-Arroyo, I.; Morales, A.; Ordaz-Rosado, D.; Garcia-Latorre, E.; Escamilla, J.; Sanchez-Pena, L. C.; Saqui-Salces, M.; Gamboa-Dominguez, A.; Vera, E.; Uribe-Ramirez, M.; Murbartian, J.; Ortiz, C. S.; Rivera-Guevara, C.; De Vizcaya-Ruiz, A.; Camacho, J. Estrogens and human papilloma virus oncogenes regulate human ether-a-go-go-1 potassium channel expression Cancer Res. 2009, 69, 3300-3307
54. Restrepo-Angulo, I.; Sanchez-Torres, C.; Camacho, J. Human EAG1 potassium channels in the epithelial-to-mesenchymal transition in lung cancer cells Anticancer Res. 2011, 31, 1265-1270
55. Borowiec, A. S.; Hague, F.; Harir, N.; Guenin, S.; Guerineau, F.; Gouilleux, F.; Roudbaraki, M.; Lassoued, K.; Ouadid-Ahidouch, H. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation J. Cell Physiol.. 2007, 212, 690-701
56. Roy, J.; Vantol, B.; Cowley, E. A.; Blay, J.; Linsdell, P. Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7 Oncol. Rep. 2008, 19, 1511-1516
57. Matsumoto, S.; Yamazoe, Y. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine Br. J. Clin. Pharmacol. 2001, 51, 133-142
58. Karatas, H.; Townsend, E. C.; Cao, F.; Chen, Y.; Bernard, D.; Liu, L.; Lei, M.; Dou, Y.; Wang, S. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction J. Am. Chem. Soc. 2013, 135, 669-682
59. Cao, F.; Townsend, E. C.; Karatas, H.; Xu, J.; Li, L.; Lee, S.; Liu, L.; Chen, Y.; Ouillette, P.; Zhu, J.; Hess, J. L.; Atadja, P.; Lei, M.; Qin, Z. S.; Malek, S.; Wang, S.; Dou, Y. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia Mol. Cell 2014, 53, 247-261
60. Zhou, H.; Liu, L.; Huang, J.; Bernard, D.; Karatas, H.; Navarro, A.; Lei, M.; Wang, S. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction J. Med. Chem. 2013, 56, 1113-1123
61. Grembecka, J.; He, S.; Shi, A.; Purohit, T.; Muntean, A. G.; Sorenson, R. J.; Showalter, H. D.; Murai, M. J.; Belcher, A. M.; Hartley, T.; Hess, J. L.; Cierpicki, T. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia Nat. Chem. Biol. 2012, 8, 277-84
62. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J. W.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 903-916
63. Asangani, I. A.; Dommeti, V. L.; Wang, X.; Malik, R.; Cieslik, M.; Yang, R.; Escara-Wilke, J.; Wilder-Romans, K.; Dhanireddy, S.; Engelke, C.; Iyer, M. K.; Jing, X.; Wu, Y. M.; Cao, X.; Qin, Z. S.; Wang, S.; Feng, F. Y.; Chinnaiyan, A. M. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer Nature 2014, 510, 278-282
64. Zhou, S. F.; Chan, S. Y.; Goh, B. C.; Chan, E.; Duan, W.; Huang, M.; McLeod, H. L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs Clinical Pharmacokinetics 2005, 44, 279-304
65. Zhou, Z.; Vorperian, V. R.; Gong, Q.; Zhang, S.; January, C. T. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole J. Cardiovasc. Electrophysiol. 1999, 10, 836-843
66. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
67. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening J. Med. Chem. 2004, 47, 1750-1759
68. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-96
69. Xu, C.; Bian, C.; Yang, W.; Galka, M.; Ouyang, H.; Chen, C.; Qiu, W.; Liu, H.; Jones, A. E.; MacKenzie, F.; Pan, P.; Li, S. S.; Wang, H.; Min, J. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2) Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 19266-19271
70. Lundblad, J. R.; Laurance, M.; Goodman, R. H. Fluorescence polarization analysis of protein-DNA and protein-protein interactions Mol. Endocrinol. 1996, 10, 607-612
71. Munson, P. J.; Rodbard, D. An exact correction to the 'Cheng-Prusoff' correction J. Recept. Res. 1988, 8, 533-546
72. Swillens, S. Interpretation of binding curves obtained with high receptor concentrations-practical aid for computer-analysis Mol. Pharmacol. 1995, 47, 1197-1203
73. Nikolovska-Coleska, Z.; Wang, R. X.; Fang, X. L.; Pan, H. G.; Tomita, Y.; Li, P.; Roller, P. P.; Krajewski, K.; Saito, N. G.; Stuckey, J. A.; Wang, S. M. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization Anal. Biochem. 2004, 332, 261-273
74. Niesen, F. H.; Berglund, H.; Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability Nat. Protoc. 2007, 2, 2212-2221
75. Chen, B.; Ye, F.; Yu, L.; Jia, G.; Huang, X.; Zhang, X.; Peng, S.; Chen, K.; Wang, M.; Gong, S.; Zhang, R.; Yin, J.; Li, H.; Yang, Y.; Liu, H.; Zhang, J.; Zhang, H.; Zhang, A.; Jiang, H.; Luo, C.; Yang, C. G. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor J. Am. Chem. Soc. 2012, 134, 17963-17971